Posted inCardiology news Specialties
Vutrisiran’s Impact on Cardiac Function and Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights from HELIOS-B
Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.